Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.50)
# 295
Out of 5,115 analysts
119
Total ratings
50.46%
Success rate
27.62%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Maintains: Buy | $26 → $38 | $22.77 | +66.89% | 8 | Jan 22, 2026 | |
| FBLG FibroBiologics | Reiterates: Buy | $5 | $0.33 | +1,406.93% | 8 | Jan 2, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.41 | +325.53% | 3 | Dec 2, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.63 | +1,180.00% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $30.89 | +81.29% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $13.67 | +90.20% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $18.37 | +139.52% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $64.54 | +36.35% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.04 | +49.25% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $1.78 | +798.88% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $15.82 | +253.98% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.31 | +246.32% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $7.69 | +30.04% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.36 | +86.57% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $21.55 | +48.53% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $8.86 | +306.32% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $489.44 | -94.28% | 1 | Aug 22, 2023 |
Kodiak Sciences
Jan 22, 2026
Maintains: Buy
Price Target: $26 → $38
Current: $22.77
Upside: +66.89%
FibroBiologics
Jan 2, 2026
Reiterates: Buy
Price Target: $5
Current: $0.33
Upside: +1,406.93%
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.41
Upside: +325.53%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.63
Upside: +1,180.00%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $30.89
Upside: +81.29%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $13.67
Upside: +90.20%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $18.37
Upside: +139.52%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $64.54
Upside: +36.35%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.04
Upside: +49.25%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $1.78
Upside: +798.88%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $15.82
Upside: +253.98%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.31
Upside: +246.32%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $7.69
Upside: +30.04%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.36
Upside: +86.57%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $21.55
Upside: +48.53%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $8.86
Upside: +306.32%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $489.44
Upside: -94.28%